Genesis Biopharma, Inc. (OTCBB: GNBP) is developing autologous cell therapies for the treatment of cancer.
Our lead product candidate, Cōntego™, is being developed as a ready-to-infuse autologous cell therapy using tumor infiltrating lymphocytes (TILs) indicated for the treatment of metastatic melanoma. Cōntego™ is based on the successful adoptive cell therapy using tumor infiltrating lymphocyte therapeutic regimen invented by Dr. Steven A. Rosenberg, Chief, Surgery Branch, Center for Cancer Research, National Cancer Institute for the treatment of metastatic melanoma[1],[2]. Dr. Rosenberg’s adoptive cell therapy is presently available as a physician-sponsored investigational therapy for the treatment of Stage IV metastatic melanoma at the National Cancer Institute, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.
Genesis Biopharma is led by a seasoned management team and world-class board of directors, with input from a prestigious scientific and medical advisory board.
[1] Rosenberg, SA and Dudley, ME, in Current Opinion in Immunology 21:233-240 (2009)
[2] Rosenberg, SA, Yang, JC, Sherry, RM, Kammula, US, Hughes, MS, Phan, GQ, Citrin, DE, Restifo, NP, Robbins, PF, Wunderlich, JR, Morton, KE, Laurencot, CM, Steinberg, SM, White, DE, Dudley, ME, in Clin Cancer Research, published OnlineFirst, American Association for Cancer Research, April 15, 2011.